Şule Yüksel Appointed Corporate Communications and Patient Initiative Manager at AIFD
19.03.2026
Şule Yüksel, who has been responsible for the communications dimension of corporate communications, patient initiative, and international industry advocacy activities at AIFD, was appointed Corporate Communications and Patient Initiative Manager as of February 2026.
AIFD which works to accelerate access to innovative medicines and treatments in Türkiye and to enhance the country’s global competitiveness in pharmaceutical research and development, continues to strengthen its communications organization. Having taken on increasing responsibilities within the association since 2018, Şule Yüksel was appointed to the position of AIFD Corporate Communications and Patient Initiative Manager as of February 2026. Since 2022, Yüksel has served as Corporate Communications and Patient Association Relations Specialist at the association and has also led the AIFD Corporate Communications and Advocacy Executive Group as well as the Patient Initiative Executive Group. In her new role, Yüksel will continue her leadership in these two key strategic structures of AIFD while focusing on aligning communications and patient initiative–focused activities with the international agenda, particularly in relation to the organizations of which AIFD is a member: the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA).
Şule Yüksel began her career at AIFD in 2018 as a Corporate Communications and Sectoral Policies Intern. After graduating in 2021 from Marmara University with a double major in Psychology and Public Relations, she assumed the role of Assistant Specialist for Corporate Communications and Patient Association Relations in August 2021. In December 2022, Yüksel was appointed Corporate Communications and Patient Association Relations Specialist. Through her expanding responsibilities in corporate communications, clinical research, and patient initiative projects, she has strengthened the narrative around AIFD’s advocacy priorities by addressing the communications dimension of the association’s institutional positioning within a strategic framework and by expanding engagement with its stakeholders.